Curious about today's AI digest?ai-tldr.dev

Daily Digest

BriefMarket · neutralLow impact
Esc
A person stands in front of an Australian Securities Exchange (ASX) share price board showing the day's top gainers
Photo: Reuters via Investing.com

Mayne Pharma Stock Jumps 86% After Richter Takeover Deal

Global Banking & Finance (Reuters)2 min read6 sources

Why is Mayne Pharma stock up today?

Mayne Pharma (MYX) stock jumped about 86% to A$5.97 on Tuesday after Hungary's Gedeon Richter agreed to buy the drugmaker for A$6.40 a share in cash, a takeover valuing it at about A$604M.

Key numbers

Offer price (cash)A$6.40+99.4% vs Nov 16 close
Deal valueA$604Mabout US$408M
Mayne share priceA$5.97+86% on Tuesday
Premium to 30-day average price124%per Inside FMCG
Top-3 holders backing deal22.14%of Mayne shares

What happened

Mayne Pharma (MYX) stock jumped about 86% to A$5.97 on Tuesday after Hungary's Gedeon Richter agreed to buy the drugmaker for A$6.40 a share in cash, a takeover valuing it at about A$604M. Richter will pay with its own cash, so the deal has no financing condition. The price is 99.4% above Monday's closing price and 124% above the average price over the past 30 days. Mayne sells women's health and skin medicines in the US, which Richter wants to grow. Shareholders vote in late January, and completion is targeted for March 2027.

Why it matters

Mayne Pharma shareholders are set to receive A$6.40 in cash for each share, nearly double the price the day before. The deal is not final yet. It needs approval from shareholders, a court and Australia's foreign investment regulator (FIRB). Mayne's last takeover bid, from US firm Cosette, was blocked by the Australian government on national-interest grounds, so regulator approval is a key step.

Who this affects

Marketneutral
Low impact
Small effect on the wider market; Mayne holders gain.
Companybullish
High impact
Mayne shareholders get a 99.4% premium; company loses independence.
Competitorsneutral
Low impact
US women's health rivals face a better-funded Richter.
Industryneutral
Low impact
Overseas drugmakers keep seeking US women's health assets.

Mayne Pharma vs Organon, Amneal, Perrigo

Mayne PharmaMYX:ASX~A$563M+86%—
OrganonOGN———
Amneal PharmaceuticalsAMRX———
PerrigoPRGO———

As of 2026-11-17

How we got here

  1. Australia blocks US firm Cosette's A$7.40-a-share takeover of Mayne on national-interest grounds

  2. Mayne shares close at about A$3.21, the base for Richter's 99.4% premium

  3. Richter and Mayne announce the A$6.40 cash deal; Mayne shares jump about 86%

What to watch

  • Mayne shareholder vote on the scheme, plus the independent expert's report on whether the deal is fair2027-01
  • Foreign investment (FIRB) approval and completion of Mayne's international unit sale to Evaris PharmaQ1 2027
  • Court hearing and targeted deal completion2027-03

Educational content only. Not investment advice.

More briefsAll briefs →